2-(4-Amino-1-oxoisoindolin-2-yl)pentanedioic acid, 95%, 100mg

9-[[2-(acetyloxy)-1-(hydroxymethyl)ethoxy]methyl]-2-amino-1,9-dihydro-6h-purin-6-one, 97%, 25g

1-((2R,3R,4R,5R)-3-chloro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione, 97%, 100mg

5,6-dihydro-4H-cyclopenta[b]thiophene-2-carbaldehyde, 250mg

Boc-Asn-OH, 98%, 1g

5,6,7,8-Tetrahydro-quinolin-8-ol, 97.0%, 5g

3-Ethoxy-4-fluorobenzaldehyde, 95.0%, 10g

1-(4-Nitro-3-trifluoromethylphenyl)-piperazine, 98.0%, 1g

4-Bromo-2-formylbenzonitrile, 97.0%, 5g

Plan stress-free PLPOLi 10x/0.25 IOS objective for iScope incident polarization, no cover glass correction. Working distance 10 mm

4-[7,12,17-tris(4-bromophenyl)-21,22,23,24-tetraazapentacyclo[16.2.1.1�,?.1?,��.1��,�?]tetracosa-1,3(24),4,6,8,10,12,14,16,18(21),19-undecaen-2-yl]phenol, 95%, 250mg

2-Nitro-5-(trifluoromethyl)benzonitrile, 95.0%, 25g

5-Amino-2-methoxyphenol, 95.0%, 5g